RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The dissociation between virological and immunological responses to HAART

Authorized Users Only
2005
Authors
Jevtović, Đorđe
Salemović, Dubravka
Ranin, Jovan
Pešić, I.
Zerjav, S
Đurković-Đaković, Olgica
Article (Published version)
Metadata
Show full item record
Abstract
While HAART allows for the reconstitution- of immune functions in most treated HIV patients, discrepant responses including failure to achieve a significant increase in circulating CD4+ T cells despite undetectable plasma viral loads (pVL), or a good immunological response while not reaching undetectabie viremia, may occur. Thus, to evaluate the incidence of and risk factors for discrepant responses to HAART, we conducted a retrospective study of all 446 patients treated with HAART between 1 January 1998 and 31 August 2004 in our HIV unit. CD4+ T cell counts and pVL values at baseline and end of study were parameters of the type of response. Within a mean follow-up period of 33 months, discrepant immunological and virological responses occurred in even 50% patients. Of these, 174(39%) did not have a rise in CD4+ T cells to above 400 per mu l despite a good virological response (type 1 dissociation), while 49 (11.0%) had a rise in the CD4+ T cell count to at least 200 per mu l but their... pVL was not undetectable (type 2 dissociation). The risk factors for immunological failure despite an undetectable pVL were baseline CD4+ T cells below 100 per mu l (OR 1.44, 95%CI 1.02-2.03) and HAART composed of three NRTIs (OR 1.92,95% CI 1.35-2.73), while usage of two NRTIs in combination with PI(s) (OR 0.36,95% CI 0.2 6-0.49), as well as simultaneous usage of all three drug classes (OR 0.37, 95% CI 0.26-0.53) were shown to be protective. The usage of PI-containing HAART regimens was protective against type 2 dissociation (OR = 0.40, 95% CI 0.19-0.83). Importantly, there were no differences in the survival of HAART-treated patients irrespective of the type of response.

Keywords:
HIV / HAART / virological/immunological dissociation
Source:
Biomedicine & Pharmacotherapy, 2005, 59, 8, 446-451
Publisher:
  • Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux

DOI: 10.1016/j.biopha.2005.07.006

ISSN: 0753-3322

PubMed: 16140494

WoS: 000232464500004

Scopus: 2-s2.0-25644432892
[ Google Scholar ]
27
26
URI
http://rimi.imi.bg.ac.rs/handle/123456789/114
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Jevtović, Đorđe
AU  - Salemović, Dubravka
AU  - Ranin, Jovan
AU  - Pešić, I.
AU  - Zerjav, S
AU  - Đurković-Đaković, Olgica
PY  - 2005
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/114
AB  - While HAART allows for the reconstitution- of immune functions in most treated HIV patients, discrepant responses including failure to achieve a significant increase in circulating CD4+ T cells despite undetectable plasma viral loads (pVL), or a good immunological response while not reaching undetectabie viremia, may occur. Thus, to evaluate the incidence of and risk factors for discrepant responses to HAART, we conducted a retrospective study of all 446 patients treated with HAART between 1 January 1998 and 31 August 2004 in our HIV unit. CD4+ T cell counts and pVL values at baseline and end of study were parameters of the type of response. Within a mean follow-up period of 33 months, discrepant immunological and virological responses occurred in even 50% patients. Of these, 174(39%) did not have a rise in CD4+ T cells to above 400 per mu l despite a good virological response (type 1 dissociation), while 49 (11.0%) had a rise in the CD4+ T cell count to at least 200 per mu l but their pVL was not undetectable (type 2 dissociation). The risk factors for immunological failure despite an undetectable pVL were baseline CD4+ T cells below 100 per mu l (OR 1.44, 95%CI 1.02-2.03) and HAART composed of three NRTIs (OR 1.92,95% CI 1.35-2.73), while usage of two NRTIs in combination with PI(s) (OR 0.36,95% CI 0.2 6-0.49), as well as simultaneous usage of all three drug classes (OR 0.37, 95% CI 0.26-0.53) were shown to be protective. The usage of PI-containing HAART regimens was protective against type 2 dissociation (OR = 0.40, 95% CI 0.19-0.83). Importantly, there were no differences in the survival of HAART-treated patients irrespective of the type of response.
PB  - Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux
T2  - Biomedicine & Pharmacotherapy
T1  - The dissociation between virological and immunological responses to HAART
EP  - 451
IS  - 8
SP  - 446
VL  - 59
DO  - 10.1016/j.biopha.2005.07.006
UR  - conv_1695
ER  - 
@article{
author = "Jevtović, Đorđe and Salemović, Dubravka and Ranin, Jovan and Pešić, I. and Zerjav, S and Đurković-Đaković, Olgica",
year = "2005",
abstract = "While HAART allows for the reconstitution- of immune functions in most treated HIV patients, discrepant responses including failure to achieve a significant increase in circulating CD4+ T cells despite undetectable plasma viral loads (pVL), or a good immunological response while not reaching undetectabie viremia, may occur. Thus, to evaluate the incidence of and risk factors for discrepant responses to HAART, we conducted a retrospective study of all 446 patients treated with HAART between 1 January 1998 and 31 August 2004 in our HIV unit. CD4+ T cell counts and pVL values at baseline and end of study were parameters of the type of response. Within a mean follow-up period of 33 months, discrepant immunological and virological responses occurred in even 50% patients. Of these, 174(39%) did not have a rise in CD4+ T cells to above 400 per mu l despite a good virological response (type 1 dissociation), while 49 (11.0%) had a rise in the CD4+ T cell count to at least 200 per mu l but their pVL was not undetectable (type 2 dissociation). The risk factors for immunological failure despite an undetectable pVL were baseline CD4+ T cells below 100 per mu l (OR 1.44, 95%CI 1.02-2.03) and HAART composed of three NRTIs (OR 1.92,95% CI 1.35-2.73), while usage of two NRTIs in combination with PI(s) (OR 0.36,95% CI 0.2 6-0.49), as well as simultaneous usage of all three drug classes (OR 0.37, 95% CI 0.26-0.53) were shown to be protective. The usage of PI-containing HAART regimens was protective against type 2 dissociation (OR = 0.40, 95% CI 0.19-0.83). Importantly, there were no differences in the survival of HAART-treated patients irrespective of the type of response.",
publisher = "Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux",
journal = "Biomedicine & Pharmacotherapy",
title = "The dissociation between virological and immunological responses to HAART",
pages = "451-446",
number = "8",
volume = "59",
doi = "10.1016/j.biopha.2005.07.006",
url = "conv_1695"
}
Jevtović, Đ., Salemović, D., Ranin, J., Pešić, I., Zerjav, S.,& Đurković-Đaković, O.. (2005). The dissociation between virological and immunological responses to HAART. in Biomedicine & Pharmacotherapy
Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux., 59(8), 446-451.
https://doi.org/10.1016/j.biopha.2005.07.006
conv_1695
Jevtović Đ, Salemović D, Ranin J, Pešić I, Zerjav S, Đurković-Đaković O. The dissociation between virological and immunological responses to HAART. in Biomedicine & Pharmacotherapy. 2005;59(8):446-451.
doi:10.1016/j.biopha.2005.07.006
conv_1695 .
Jevtović, Đorđe, Salemović, Dubravka, Ranin, Jovan, Pešić, I., Zerjav, S, Đurković-Đaković, Olgica, "The dissociation between virological and immunological responses to HAART" in Biomedicine & Pharmacotherapy, 59, no. 8 (2005):446-451,
https://doi.org/10.1016/j.biopha.2005.07.006 .,
conv_1695 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB